Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
about
How do we prepare ourselves for a new paradigm of medicine to advance the treatment of pediatric acute lymphoblastic leukemia?Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsMercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fictionPharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyThiopurine methyltransferase genotyping in Palestinian childhood acute lymphoblastic leukemia patients.Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapyMethylenetetrahydrofolate reductase C677T and overall survival in pediatric acute lymphoblastic leukemia: a systematic review.Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphismPaediatric clinical pharmacology in the UK.Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenClinical implication of thiopurine methyltransferase polymorphism in children with acute lymphoblastic leukemia: A preliminary Egyptian study.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Pharmacogenomics and adverse drug reactions in children.Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.Pediatric perspective on pharmacogenomics.Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.Pharmacogenetics of childhood acute lymphoblastic leukemia.Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia.Harnessing Solute Carrier Transporters for Precision Oncology.Can anthocyanins improve maintenance therapy of Ph(+) acute lymphoblastic leukaemia?Systematic identification of host genomic variation related to treatment outcome of childhood acute lymphoblastic leukemia.Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia.
P2860
Q24568045-168320A7-7CD9-4861-9166-14A5A9F661B0Q24633763-9970307C-AED1-49B4-BC17-27651FD6F082Q27023839-FB1CDEA6-CB24-4991-ACD4-1A6FD4167426Q28083449-166C6464-9513-4734-AAD1-5F45B5750382Q31150912-565143AD-4FFB-46A9-AA4D-0E19693A3676Q34323258-C959B117-7E3C-4B17-82F8-21E9F4F3AEACQ34336668-7A4EA5A9-4DB0-475C-8309-6CD907EE47E3Q34429411-A4D587D6-4133-49E0-BD98-F243D42BF000Q34607600-6A287579-9DD7-455D-862A-CE77C69CC91CQ35135954-91AAE87E-5DAF-4C9F-B802-D5BEA8E9CD96Q36291554-92C72401-0AD4-4AE5-A476-F48E65A2051AQ36322918-44435672-F027-4011-87E0-D195B9BE686DQ36458023-74FB921A-1DC1-48DD-8CEE-35C25460F55CQ37685527-16A7197A-B24A-4382-9861-21AA7F9C89B3Q37719025-54ACD550-EA69-4E72-916C-9FC78B5734D4Q38063197-BC9132BA-AB3D-422E-B369-0DD16DD2E3FEQ38162869-0A6A310F-81E2-45E0-B847-40CB4AA7EECBQ38199738-89DF7EAF-BE96-44E9-BDD0-DBE7292E3732Q38243175-DE4F1623-B003-4DF1-B4EF-5BB501318582Q38855568-9AE388B3-5756-4DFF-9051-9B9B65F10B46Q39204754-7B8FF6BB-FF8D-45EA-A162-1B6071CA42CDQ39215315-1B546D47-AE26-4347-8466-351C785CC8B0Q43570221-6E8BDFA4-7E3E-4DE1-AAAE-15645AE3647DQ53517804-ACD0CC2A-8277-4ACF-9D5A-3E7E71D3811B
P2860
Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacogenetic determinants o ...... acute lymphoblastic leukemia.
@en
Pharmacogenetic determinants o ...... acute lymphoblastic leukemia.
@nl
type
label
Pharmacogenetic determinants o ...... acute lymphoblastic leukemia.
@en
Pharmacogenetic determinants o ...... acute lymphoblastic leukemia.
@nl
prefLabel
Pharmacogenetic determinants o ...... acute lymphoblastic leukemia.
@en
Pharmacogenetic determinants o ...... acute lymphoblastic leukemia.
@nl
P2860
P1476
Pharmacogenetic determinants o ...... acute lymphoblastic leukemia.
@en
P2093
Tiphaine Adam de Beaumais
P2860
P2888
P304
P356
10.1007/S00228-012-1251-4
P577
2012-03-16T00:00:00Z